carvedilol has been researched along with Diabetes Mellitus in 18 studies
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study the development of new onset diabetes in a large cohort of patients with heart failure treated with either metoprolol or carvedilol." | 9.12 | Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). ( Charlesworth, A; Cleland, JG; Di Lenarda, A; Lukas, MA; Metra, M; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "Although prior literature suggests that metoprolol may worsen glucose control compared to carvedilol, whether this has clinical relevance among older adults with diabetes and heart failure (HF) remains an open question." | 8.02 | Risk of clinically relevant hyperglycemia with metoprolol compared to carvedilol in older adults with heart failure and diabetes. ( Dave, CV; Dejanovic, I; Gerhard, T; Horton, DB; Kobylarz, FA; Nyandege, A; Setoguchi, S; Strom, BL; Tseng, CL, 2021) |
| "Long term carvedilol therapy appears to be associated with a higher overall survival rate, improvement in ejection fraction and NYHA class in heart failure patients with preserved ejection fraction." | 7.91 | Effects of carvedilol therapy in patients with heart failure with preserved ejection fraction - Results from the Croatian heart failure (CRO-HF) registry. ( Branka, JZ; Davor, M; Domagoj, M; Duska, G; Jelena, M, 2019) |
| "The Japanese Diastolic Heart Failure Study (J-DHF) has suggested beneficial effects of the standard-dose prescription of carvedilol in heart failure with preserved ejection fraction (HFPEF)." | 7.80 | Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF). ( Hori, M; Izumi, C; Origasa, H; Sakata, Y; Shinozaki, T; Suzuki, Y; Taira, K; Takahashi, T; Watanabe, T; Yamamoto, K, 2014) |
| "To assess the efficacy and tolerability of carvedilol administration in patients with heart failure and concomitant diabetes." | 7.72 | Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus. ( Dei Cas, A; Dei Cas, L; Metra, M; Nodari, S, 2003) |
| "Carvedilol was associated with conventional optimised treatment in 64% of diabetics and 65% of non-diabetics (P = NS)." | 6.73 | Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure. ( Cioffi, G; De Feo, S; Del Sindaco, D; Di Lenarda, A; Giovannini, E; Leggio, F; Minardi, G; Opasich, C; Pulignano, G; Tarantini, L, 2007) |
| "To study the development of new onset diabetes in a large cohort of patients with heart failure treated with either metoprolol or carvedilol." | 5.12 | Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). ( Charlesworth, A; Cleland, JG; Di Lenarda, A; Lukas, MA; Metra, M; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "Although prior literature suggests that metoprolol may worsen glucose control compared to carvedilol, whether this has clinical relevance among older adults with diabetes and heart failure (HF) remains an open question." | 4.02 | Risk of clinically relevant hyperglycemia with metoprolol compared to carvedilol in older adults with heart failure and diabetes. ( Dave, CV; Dejanovic, I; Gerhard, T; Horton, DB; Kobylarz, FA; Nyandege, A; Setoguchi, S; Strom, BL; Tseng, CL, 2021) |
| "Long term carvedilol therapy appears to be associated with a higher overall survival rate, improvement in ejection fraction and NYHA class in heart failure patients with preserved ejection fraction." | 3.91 | Effects of carvedilol therapy in patients with heart failure with preserved ejection fraction - Results from the Croatian heart failure (CRO-HF) registry. ( Branka, JZ; Davor, M; Domagoj, M; Duska, G; Jelena, M, 2019) |
| "The Japanese Diastolic Heart Failure Study (J-DHF) has suggested beneficial effects of the standard-dose prescription of carvedilol in heart failure with preserved ejection fraction (HFPEF)." | 3.80 | Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF). ( Hori, M; Izumi, C; Origasa, H; Sakata, Y; Shinozaki, T; Suzuki, Y; Taira, K; Takahashi, T; Watanabe, T; Yamamoto, K, 2014) |
| "This prospective post-marketing drug use survey was conducted to assess the safety and efficacy of the β-adrenergic receptor antagonist (β-blocker) Artist® Tablets (carvedilol) in patients with hypertension in Japan." | 3.77 | Artist® tablets (carvedilol) for hypertensive patients in Japan: results of a drug use survey. ( Hiramatsu, K; Iizuka, T; Komiya, M; Matsumoto, T; Mori, Y; Nishikawa, Y; Zenimura, N, 2011) |
| "To assess the efficacy and tolerability of carvedilol administration in patients with heart failure and concomitant diabetes." | 3.72 | Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus. ( Dei Cas, A; Dei Cas, L; Metra, M; Nodari, S, 2003) |
| "Carvedilol was associated with conventional optimised treatment in 64% of diabetics and 65% of non-diabetics (P = NS)." | 2.73 | Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure. ( Cioffi, G; De Feo, S; Del Sindaco, D; Di Lenarda, A; Giovannini, E; Leggio, F; Minardi, G; Opasich, C; Pulignano, G; Tarantini, L, 2007) |
| " This study assesses the impact of β-blocker type and dosing on survival in patients with DM after MI." | 1.91 | Impact of Diabetes Mellitus on Benefit of β-Blocker Therapy After Myocardial Infarction. ( Abbott, JD; Bello, D; Blandon, C; Goldberger, JJ; Subačius, H; Zaatari, G, 2023) |
| "Carvedilol is a third-generation β-adrenoceptor antagonist, which also stimulates β-arrestins." | 1.56 | Metabolic effects of carvedilol through β-arrestin proteins: investigations in a streptozotocin-induced diabetes rat model and in C2C12 myoblasts. ( Güven, B; Kara, Z; Onay-Beşikci, A, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (44.44) | 29.6817 |
| 2010's | 7 (38.89) | 24.3611 |
| 2020's | 3 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Zaatari, G | 1 |
| Bello, D | 1 |
| Blandon, C | 1 |
| Abbott, JD | 1 |
| Subačius, H | 1 |
| Goldberger, JJ | 1 |
| Güven, B | 1 |
| Kara, Z | 1 |
| Onay-Beşikci, A | 1 |
| Dave, CV | 1 |
| Strom, BL | 1 |
| Kobylarz, FA | 1 |
| Horton, DB | 1 |
| Gerhard, T | 1 |
| Tseng, CL | 1 |
| Dejanovic, I | 1 |
| Nyandege, A | 1 |
| Setoguchi, S | 1 |
| Domagoj, M | 1 |
| Branka, JZ | 1 |
| Jelena, M | 1 |
| Davor, M | 1 |
| Duska, G | 1 |
| Saeidnia, S | 1 |
| Abdollahi, M | 1 |
| Yamamoto, K | 1 |
| Origasa, H | 1 |
| Suzuki, Y | 1 |
| Takahashi, T | 1 |
| Shinozaki, T | 1 |
| Watanabe, T | 1 |
| Sakata, Y | 1 |
| Izumi, C | 1 |
| Taira, K | 1 |
| Hori, M | 1 |
| Giles, TD | 1 |
| Remme, WJ | 2 |
| Fonseca, V | 1 |
| Sharma, PP | 1 |
| Shah, M | 1 |
| Deedwania, P | 1 |
| Mori, Y | 1 |
| Nishikawa, Y | 1 |
| Iizuka, T | 1 |
| Zenimura, N | 1 |
| Matsumoto, T | 1 |
| Hiramatsu, K | 1 |
| Komiya, M | 1 |
| Monami, M | 1 |
| Filippi, L | 1 |
| Ungar, A | 1 |
| Sgrilli, F | 1 |
| Antenore, A | 1 |
| Dicembrini, I | 1 |
| Bagnoli, P | 1 |
| Marchionni, N | 1 |
| Rotella, CM | 1 |
| Mannucci, E | 1 |
| Kobayakawa, N | 1 |
| Sawaki, D | 1 |
| Otani, Y | 1 |
| Sekita, G | 1 |
| Fukushima, K | 1 |
| Takeuchi, H | 1 |
| Aoyagi, T | 1 |
| Nodari, S | 1 |
| Metra, M | 2 |
| Dei Cas, A | 1 |
| Dei Cas, L | 1 |
| Bell, DS | 1 |
| Lukas, MA | 2 |
| Holdbrook, FK | 1 |
| Fowler, MB | 1 |
| Sarafidis, PA | 1 |
| Bakris, GL | 1 |
| Kveiborg, B | 1 |
| Christiansen, B | 1 |
| Major-Petersen, A | 1 |
| Torp-Pedersen, C | 2 |
| Charlesworth, A | 1 |
| Spark, P | 1 |
| Poole-Wilson, PA | 1 |
| Swedberg, K | 1 |
| Cleland, JG | 1 |
| Di Lenarda, A | 2 |
| Scherhag, A | 1 |
| Del Sindaco, D | 1 |
| Pulignano, G | 1 |
| Cioffi, G | 1 |
| Tarantini, L | 1 |
| De Feo, S | 1 |
| Opasich, C | 1 |
| Minardi, G | 1 |
| Giovannini, E | 1 |
| Leggio, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use of Beta-blockers and Risk of New Onset Diabetes[NCT01587638] | 12,336 participants (Actual) | Observational | 2009-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for carvedilol and Diabetes Mellitus
| Article | Year |
|---|---|
Toxicological and pharmacological concerns on oxidative stress and related diseases.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxidants; B | 2013 |
Use of beta-blockers for heart failure in patients with diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Bisoprolol; Carbazoles; Carvedilol; Diabetes C | 2002 |
Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Diabet | 2013 |
The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis.
Topics: Aged; Blood Glucose; Carbazoles; Cardiac Output, Low; Carvedilol; Diabetes Mellitus; Female; Humans; | 2006 |
Metabolic effects of beta-adrenoceptor antagonists with special emphasis on carvedilol.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Diabetes Mellitus; Glucose; Humans; In | 2006 |
3 trials available for carvedilol and Diabetes Mellitus
| Article | Year |
|---|---|
Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Diabet | 2013 |
Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET).
Topics: Adrenergic beta-Antagonists; Aged; Blood Glucose; Carbazoles; Carvedilol; Chi-Square Distribution; D | 2007 |
Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Blood Glucose; Carbazoles; Carvedilol; Diabete | 2007 |
11 other studies available for carvedilol and Diabetes Mellitus
| Article | Year |
|---|---|
Impact of Diabetes Mellitus on Benefit of β-Blocker Therapy After Myocardial Infarction.
Topics: Adrenergic beta-Antagonists; Carvedilol; Diabetes Mellitus; Humans; Metoprolol; Myocardial Infarctio | 2023 |
Metabolic effects of carvedilol through β-arrestin proteins: investigations in a streptozotocin-induced diabetes rat model and in C2C12 myoblasts.
Topics: Animals; beta-Arrestin 1; beta-Arrestin 2; beta-Arrestins; Carbazoles; Carvedilol; Diabetes Mellitus | 2020 |
Risk of clinically relevant hyperglycemia with metoprolol compared to carvedilol in older adults with heart failure and diabetes.
Topics: Aged; Carvedilol; Diabetes Mellitus; Heart Failure; Humans; Hyperglycemia; Male; Medicare; Metoprolo | 2021 |
Effects of carvedilol therapy in patients with heart failure with preserved ejection fraction - Results from the Croatian heart failure (CRO-HF) registry.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Carvedilol; Comorbidity; Croatia; Diabetes Mel | 2019 |
Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction - a report from the Japanese Diastolic Heart Failure Study (J-DHF).
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Body Mass Index; Carbazoles; Carvedilol; Diabe | 2014 |
Which beta-blocker is most effective in heart failure?
Topics: Adrenergic beta-Antagonists; Animals; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Clinical Tria | 2010 |
Risk of new-onset diabetes mellitus associated with beta-blocker treatment for hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Age of Onset; Aged; Antihypertensive Agents; Carbazoles; Carvedi | 2011 |
Artist® tablets (carvedilol) for hypertensive patients in Japan: results of a drug use survey.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and ove | 2011 |
A case of severe diabetes mellitus occurred during management of heart failure with carvedilol and furosemide.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Diabetes Mellitus; Diuretics; Drug Thera | 2003 |
Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Cardiac Catheterization; Carvedilol; Chronic Disease; | 2003 |
Do the metabolic effects of beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Glucose; Carbazoles; Carvedilol; Diabete | 2006 |